Study guide

7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

Oregon Multistate Pharmacy Jurisprudence Examination MPJE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Oregon Legal Framework

1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy

2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities

2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection

3 Chapter 3: Pharmacy Technicians, Interns & Preceptors

3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision

4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners

4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)

5 Chapter 5: Prescriber Authority & Prescription Requirements

5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority

6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine

7 Chapter 7: Counseling, Language Access & Confidentiality

7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

8 Chapter 8: The Dispensing Process

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse

9 Chapter 9: Nonprescription & Restricted Products

9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others

10 Chapter 10: Product Selection: Generic & Biologic Substitution

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting

11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings

12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies

13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice

13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks

7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

Key Takeaways Explain This Topic AI

Oregon licensees may disclose patient information without consent only to the Board, to providers when a pharmacist authorizes it for the patient's health, as law authorizes or requires, as confidentiality laws permit, or to the patient.

Under OAR 855-104-0015, an Oregon licensee may not access or obtain patient information except for patient care, even without disclosing it.

Oregon pharmacies must provide patients' records within 30 days and may not deny copies because of inability to pay.

HIPAA lets pharmacies disclose PHI for treatment, payment and operations, requires notice of a breach within 60 days, and in 2025 a court vacated most of its 2024 reproductive-health amendments.

Oregon PDMP data is confidential, may not be used commercially, and reaches law enforcement only through a court order based on probable cause.

Last updated: October 2026

Why this matters

Area 2.5 includes "protecting patient and health record confidentiality." Oregon pharmacists must satisfy three layers: the Board's universal confidentiality rule (OAR 855-104-0015), HIPAA , and special-category rules such as 42 CFR Part 2 for substance use disorder records and the PDMP statute. Exam items typically ask whether a disclosure is allowed and to whom.

Oregon's confidentiality rule (OAR 855-104-0015)

A licensee or registrant who obtains patient information may not disclose it to a third party without the patient's consent , except:

To the Board .

To a practitioner, pharmacist, intern, technician or registrant , if a pharmacist authorizes the disclosure and it is necessary to protect the patient's health or well-being .

To a third party when disclosure is authorized or required by law .

As permitted by federal and state confidentiality laws (HIPAA and Oregon's health-information statutes, ORS 192.553–.581).

To the patient , or to persons the patient authorizes.

The rule also bars accessing or obtaining patient information except for patient care (or one of those exceptions). Looking up a neighbor's or ex-spouse's profile is a violation even if nothing is disclosed. Pharmacists, interns and technicians each have a parallel confidentiality rule (OAR 855-115-0110, 855-120-0110, 855-125-0110).

Patients' access to their pharmacy records (OAR 855-104-0050)

Licensees and registrants must make health information in the pharmacy record available to the patient or patient's representative on request, for inspection and copying.

A reasonable cost may be charged, but a patient may not be denied summaries or copies because of inability to pay .

Requests must be met within a reasonable time, not to exceed 30 days .

Some information may be withheld. Examples are information obtained in confidence from non-health-care sources, psychotherapy notes, information compiled for legal proceedings, and information federal rules allow to be withheld.

HIPAA essentials for pharmacies

Topic Rule

Covered entity Pharmacies that bill electronically are covered entities. Their vendors with PHI access are business associates and need business associate agreements

Treatment, payment, operations (TPO) PHI may be used and disclosed for TPO without authorization. Pharmacist-to-prescriber communication about therapy is treatment

  • Minimum necessary Applies to most disclosures except those for treatment and those to the patient
  • Notice of Privacy Practices Given at first service delivery; a good-faith effort to get acknowledgment

Patient rights Access (federal HIPAA allows up to 30 days, extendable once by 30 days), amendment, accounting of disclosures, restrictions (including self-pay restrictions on disclosures to health plans), confidential communications

Family and caregivers A pharmacist may use professional judgment to let a family member or friend pick up filled prescriptions

Breach notification Notify affected individuals without unreasonable delay, and no later than 60 days after discovery

A June 18, 2025 federal court decision ( Purl v. HHS ) vacated most of the 2024 HIPAA amendments on reproductive health care privacy. Separately, updated Notice of Privacy Practices requirements tied to 42 CFR Part 2 took effect February 16, 2026 .

Substance use disorder records (42 CFR Part 2)

Records from a federally assisted SUD program have extra protection. Under the 2024 final rule, with compliance due February 16, 2026 :

Patients may sign a single consent for all future treatment, payment and operations.

HIPAA covered entities that receive records under that consent may redisclose them as HIPAA permits, except in proceedings against the patient.

A subpoena alone still does not authorize disclosure. A court order meeting Part 2 standards is required.

Oregon's HPSP statute and the PDMP statute expressly incorporate Part 2 and ORS 179.505.

PDMP confidentiality (ORS 431A.865)

PDMP data is protected health information and is not a public record . Pharmacists may access it only to evaluate or provide treatment for their patient. They may share it with other providers involved in the patient's care for care coordination. The data may not be used commercially . Law enforcement may obtain it only through a valid court order based on probable cause . Improper disclosure can bring civil damages and an Attorney General civil penalty of up to $10,000 per violation (ORS 431A.900).

Important

In Oregon, access without a patient-care purpose is itself a violation (OAR 855-104-0015(3)). A technician who looks up a celebrity's prescription history commits a Board violation and a HIPAA violation, even if they never tell anyone.

Disclosures to law enforcement and others

Law enforcement: HIPAA permits limited disclosures in response to a court order, warrant or qualifying administrative request, and in other narrow cases. Oregon's PDMP requires a court order. Precursor (pseudoephedrine) logs are available to law enforcement through a lawful subpoena accepted by the Board (ORS 475.230(5)(c)). Acceptable subpoenas are addressed in OAR 855-080-0029.

The Board: disclosure to the Board is always allowed (OAR 855-104-0015(2)(a)).

Public health reporting: required disclosures, such as ALERT IIS, communicable disease reporting, Death with Dignity reporting and the PDMP, are "required by law."

Exam scenario

A detective calls a Portland pharmacy and asks for a suspect's controlled substance fill history "for an active investigation," with no paperwork. The pharmacist should decline . A phone request is not an exception under OAR 855-104-0015 or HIPAA without proper legal process. The pharmacist may refer the detective to the appropriate legal process, such as a warrant, a court order, or a PDMP request through a court order based on probable cause. The pharmacist documents the request under the pharmacy's privacy policies.